JAN 24, 2019 11:46 PM PST

Why Do Promising Cancer Drugs Fail?

WRITTEN BY: Nouran Amin

After almost 20 years of a once-promising cancer drugs known as MMP inhibitors suddenly failed in clinical trials, scientists are now eager to provide an explanation.

MMP inhibitors, known as matrix metalloproteinases, originally work by targeting enzymes thought to be responsible for the spread of cancer. The results in the model C. elegans worms can lead to more effective ways to prevent the initial steps of metastasis, in what results in about 90 percent of all tumor-related deaths.

Learn more about MMPs in cancer metastasis:

Despite the promising results of MMP inhibitors in mice, they were not successful in people with some patients developing serious side effects. New findings suggest that maybe cancerous cells will convert themselves to a brute force when no dissolving enzymes are available. Findings were published in Developmental Cell.

Caption: This image shows the uncontrolled growth of cells in squamous cell carcinoma.

Credit: Markus Schober and Elaine Fuchs, The Rockefeller University, New York via NIH

The study suggested that the reason why MMPs did not work on human tumors is because--“Normal worm cells use their MMP enzymes to help cut through the matrix of proteins in the basement membrane like molecular scissors, the researchers say. But cells in "knockout" worms lacking the MMP enzymes instead build a large protrusion that pummels and smashes its way through with brute force,” said experimental leader and research scientist,” Laura Kelley.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 04, 2020
Microbiology
JUN 04, 2020
The Big Effect of a Small Protein
Sepsis and bacterial meningitis are life-threatening diseases caused by meningococci bacteria.
JUN 10, 2020
Drug Discovery & Development
JUN 10, 2020
FDA Approves New Antibiotic for Hospital-Acquired Pneumonia
The US Food and Drug Administration (FDA) has approved Recarbrio, an antibiotic drug created by pharmaceutical company M ...
JUN 13, 2020
Neuroscience
JUN 13, 2020
High Doses of Ketamine Can Switch Off the Brain
Researchers from the University of Cambridge, England, have found that high doses of ketamine temporarily switch off the ...
JUN 13, 2020
Cannabis Sciences
JUN 13, 2020
CBD Kills Brain Cancer Cells in Petri Dish
Cannabis products are not only popular for their psychoactive effects. An increasing number of companies and researchers ...
JUN 23, 2020
Drug Discovery & Development
JUN 23, 2020
Psychedelic DMT to Enter Clinical Trials
Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinic ...
JUL 05, 2020
Drug Discovery & Development
JUL 05, 2020
New Drug May Reduce Inflammation from COVID-19
Scientists from the University of Toronto have identified a new drug candidate that may reduce all kinds of inflammation ...
Loading Comments...